The potential effectiveness of the antiangiogenic agent bevacizumab in aggressive prolactinomas remains unstudied, but its role in inhibiting vascular endothelial growth factor (VEGF) has also shown promise in pituitary adenomas, where high VEGF expression is prevalent, as bevacizumab has demonstrated significant hormonal reduction and tumor stabilization in aggressive ACTH-secreting and nonfunctioning adenomas resistant to other therapies, suggesting it may also benefit prolactinomas as monotherapy or in combination with temozolomide [1, 19, 20]. The gene discussed is POMC; the disease is adenoma.